Cancer is a heterogeneous disease, requiring treatment tailored to the unique phenotype of the patient's tumor. Monoclonal antibodies (mAbs) and variants thereof have enabled targeted therapies to selectively target cancer cells. Cancer cell-specific mAbs have been used for image-guided surgery and targeted delivery of radionuclides or toxic agents, improving classical treatment strategies. Cancer cell-specific mAbs can further inhibit tumor cell growth or can stimulate immune-mediated destruction of cancer cells, a feature that has also been achieved through mAb-mediated manipulation of immune cells and pathways. Drawbacks of mAbs and their variants, together with the discovery of camelid heavy chain-only antibodies and the many advantageous features of their variable domains, referred to as VHHs, single domain antibodies or nanobodies (Nbs), resulted in the exploration of Nbs as an alternative targeting moiety. We therefore review the state-of-the-art as well as novel exploitation strategies of Nbs for targeted cancer therapy.

Originele taal-2English
Pagina's (van-tot)143-199
Aantal pagina's57
TijdschriftInternational review of cell and molecular biology
StatusPublished - 2022

Bibliografische nota

Copyright © 2022 Elsevier Inc. All rights reserved.


Duik in de onderzoeksthema's van 'Emerging applications of nanobodies in cancer therapy'. Samen vormen ze een unieke vingerafdruk.

Citeer dit